Creative Biolabs’ proprietary HostOptim™ technology enables generation of high yielding production systems across different industry relevant platforms (e.g. CHO, HEK, Pichia pastoris).
Mammalian cells have the ability to perform most comprehensive post-translational modifications and to secrete glycoproteins that are correctly folded and contain complex antennary oligosaccharides with terminal sialic acid. Mammalian cells are widely used in the production of recombinant proteins, antibodies, virus, viral-subunit proteins, and gene-therapy vectors.
Protein scientists at Creative Biolabs have experience and expertise in both transient and stable expression using a multitude of cell lines, including CHO and HEK293 expression systems. To meet different needs for protein expression, mammalian cell protein expression can be carried out via the following different approaches:
Transient burst expression
Stable mammalian cell line expression (CHO and HEK293)
CHO expression systems
CHO cells are the most commonly used mammalian cells for protein expression. Our homogeneous stable super-producer clones are obtained without cloning in just one week, whilst classical generation of stable cell lines takes 6 to 9 months. The obtained cell lines can be banked and re-used for further productions. Whereas transient transfection is very expensive at large scale, we are able to offer attractive cost reductions with scale-up.
HEK293 expression systems
Engineered Human Embryonic Kidney cells (HEK293 cells) produce native structure and biologically functional proteins with similar post-translational modification to human body. We provide one-stop-shop protein production services using transient transfection in HEK293 cells from gene sequence to purified proteins.
Contracting laboratories have direct access to the scientists working on their projects, and each project is delivered with a specifications sheet and original data on yield, purity, and identity.
The HostOptim™ paltform has been developed from our core expertise in the field of gene expression and protein synthesis, which is complementary to existing production technologies including improved promoters, vectors and other transcriptional approaches. Additional yield enhancement through better translation efficiency (more protein per mRNA) improves economics for antibodies and other biopharmaceutical proteins. This can for example make the difference in pursuing targets that otherwise would be discarded due to insufficient yields, and speed up development with significant cost savings.